A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer

By afschroeder • August 15, 2025

Cummings AL, Sussell J, Rosettie KL, Moustaid FE, Ogale S, Ngiam C, Jovanoski N, Arnold M, Lee JM. A treatment-impact model of alectinib for the prediction of recurrence and associated costs in treating resectable ALK+ non-small cell lung cancer. Lung Cancer. 2025 Aug 6;207:108701. doi: 10.1016/j.lungcan.2025.108701. Epub ahead of print. PMID: 40811940.

Tags: Alectinib, anaplastic lymphoma kinase, chemotherapy, Costs and Cost Analysis, Hematology/Oncology, Non-small cell lung cancer, Publications, Pulmonary, Critical Care & Sleep Medicine, Statistical model, Tyrosine kinase inhibitors

Early cellular events of osteomucosal healing in the tooth extraction socket

Kim S, Song M, Williams D, Du W, Cho I, Bae E, Kim J, Goswami A, Shin KH, Park NH, Kim RH. Early cellular events[...]

A novel application of LC-MS/MS accurately quantifies the labile redox pools of cellular coenzymes Q9 and Q10

Jain A, Li VW, Salem J, Reddy ST, Palaskas NJ, Meriwether D. A novel application of LC-MS/MS accurately quantifies the labile redox pools of cellular[...]

Phase I trial of ADP-A2AFP TCR T-cell therapy in patients with advanced hepatocellular or gastric hepatoid carcinoma

Meyer T, Finn RS, Borad M, Mahipal A, Edeline J, Houot R, Hausner PF, Hollebecque A, Goyal L, Frigault M, Jeffry Evans TR, Wong KM,[...]